UBS Group
TEVA icon

UBS Group’s Teva Pharmaceuticals TEVA Stock Holding History

UBS Group’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$72.5M Buy
2,140,065
+262,848
+14% +$8.75M 0.01% 1381
2026
Q1 		$56.5M Sell
1,877,217
-2,400,769
-56% -$77.2M 0.01% 1527
2025
Q4 		$134M Sell
4,277,986
-1,336,094
-24% -$32.9M 0.02% 809
2025
Q3 		$113M Buy
5,614,080
+456,692
+9% +$8.02M 0.02% 936
2025
Q2 		$86.4M Sell
5,157,388
-1,896,283
-27% -$30.6M 0.02% 1075
2025
Q1 		$108M Buy
7,053,671
+4,520,948
+179% +$80.8M 0.02% 870
2024
Q4 		$55.8M Buy
2,532,723
+889,529
+54% +$16.2M 0.01% 1363
2024
Q3 		$29.6M Sell
1,643,194
-369,941
-18% -$6.47M 0.01% 1529
2024
Q2 		$32.7M Sell
2,013,135
-185,067
-8% -$2.85M 0.01% 1323
2024
Q1 		$31M Buy
2,198,202
+1,295,758
+144% +$16.3M 0.01% 1374
2023
Q4 		$9.42M Sell
902,444
-429,968
-32% -$4.01M ﹤0.01% 2152
2023
Q3 		$13.6M Buy
1,332,412
+323,262
+32% +$3.01M ﹤0.01% 1752
2023
Q2 		$7.6M Sell
1,009,150
-42,102
-4% -$341K ﹤0.01% 2187
2023
Q1 		$9.3M Sell
1,051,252
-259,662
-20% -$2.57M ﹤0.01% 1946
2022
Q4 		$12M Sell
1,310,914
-51,277
-4% -$447K ﹤0.01% 1791
2022
Q3 		$11M Sell
1,362,191
-116,177
-8% -$1.03M ﹤0.01% 1706
2022
Q2 		$11.1M Sell
1,478,368
-450,356
-23% -$3.92M ﹤0.01% 1732
2022
Q1 		$18.1M Sell
1,928,724
-912,874
-32% -$7.62M 0.01% 1500
2021
Q4 		$22.8M Buy
2,841,598
+1,245,502
+78% +$11.2M 0.01% 1485
2021
Q3 		$15.5M Buy
1,596,096
+265,204
+20% +$2.48M ﹤0.01% 1695
2021
Q2 		$13.2M Sell
1,330,892
-131,023
-9% -$1.39M ﹤0.01% 1814
2021
Q1 		$16.9M Sell
1,461,915
-80,607
-5% -$924K 0.01% 1558
2020
Q4 		$14.9M Buy
1,542,522
+281,137
+22% +$2.69M 0.01% 1551
2020
Q3 		$11.4M Sell
1,261,385
-366,927
-23% -$3.88M ﹤0.01% 1558
2020
Q2 		$20.1M Sell
1,628,312
-156,920
-9% -$1.77M 0.01% 1084
2020
Q1 		$16M Sell
1,785,232
-64,390
-3% -$660K 0.01% 1105
2019
Q4 		$18.1M Sell
1,849,622
-459,106
-20% -$4.1M 0.01% 1451
2019
Q3 		$15.9M Buy
2,308,728
+790,970
+52% +$6.06M 0.01% 1410
2019
Q2 		$14M Sell
1,517,758
-116,218
-7% -$1.4M 0.01% 1476
2019
Q1 		$25.6M Sell
1,633,976
-114,506
-7% -$2.02M 0.01% 992
2018
Q4 		$27M Sell
1,748,482
-443,330
-20% -$9.09M 0.01% 888
2018
Q3 		$47.2M Sell
2,191,812
-252,498
-10% -$5.86M 0.02% 705
2018
Q2 		$59.4M Buy
2,444,310
+848,706
+53% +$17.3M 0.03% 570
2018
Q1 		$27.3M Buy
1,595,604
+305,767
+24% +$5.97M 0.01% 958
2017
Q4 		$24.4M Sell
1,289,837
-457,640
-26% -$6.88M 0.01% 1062
2017
Q3 		$30.8M Sell
1,747,477
-264,977
-13% -$5.96M 0.01% 860
2017
Q2 		$66.9M Buy
2,012,454
+131,020
+7% +$4.06M 0.03% 466
2017
Q1 		$60.4M Buy
1,881,434
+366,743
+24% +$12.5M 0.03% 479
2016
Q4 		$54.9M Sell
1,514,691
-25,429
-2% -$1.02M 0.03% 501
2016
Q3 		$70.9M Buy
1,540,120
+537,057
+54% +$28M 0.04% 415
2016
Q2 		$50.4M Sell
1,003,063
-138,607
-12% -$7.38M 0.03% 502
2016
Q1 		$61.1M Buy
1,141,670
+3,542
+0.3% +$208K 0.04% 409
2015
Q4 		$74.7M Buy
1,138,128
+111,449
+11% +$6.89M 0.05% 380
2015
Q3 		$58M Sell
1,026,679
-345
-0% -$22.4K 0.04% 421
2015
Q2 		$60.7M Sell
1,027,024
-224,631
-18% -$13.9M 0.04% 458
2015
Q1 		$78M Sell
1,251,655
-17,201
-1% -$1M 0.05% 374
2014
Q4 		$73M Buy
+1,268,856
New +$70.7M 0.05% 389

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

UBS Group's TEVA Position: Q2 2026 in Review

UBS Group increased its Teva Pharmaceuticals (TEVA) stake by 14% in Q2 2026, buying an estimated $8.75M and bringing the position to 2,140,065 shares worth $72.5M. The position accounts for 0.01% of the portfolio, ranked #1381.

UBS Group first reported a position in TEVA in Q4 2014 and has held it in 47 quarters since. The position peaked at $134M in Q4 2025. 672 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

  • UBS Group held 2,140,065 shares of Teva Pharmaceuticals worth $72.5M as of Q2 2026.
  • UBS Group bought 262,848 Teva Pharmaceuticals shares in Q2 2026, an estimated $8.75M.
  • Teva Pharmaceuticals made up 0.01% of UBS Group's portfolio in Q2 2026, its #1381 holding.
  • UBS Group first reported a position in Teva Pharmaceuticals in Q4 2014 and has held it in 47 quarters since.
  • UBS Group's Teva Pharmaceuticals position peaked at $134M in Q4 2025.
  • 672 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.